GlassScriptPhysician profile
Amit Chhabra
NPI 1902005622
$13,193.34
in general payments reported to CMS, 2019-2025
35 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $438 · 2021: $1,573 · 2022: $1,933 · 2023: $3,251 · 2024: $1,977 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,436 · Travel and Lodging: $789 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,436.04 |
| Travel and Lodging | $788.52 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,973.27 | 2021-2023 | Micra, Linq II |
| Biotronik INC. | $1,820.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,606.99 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $1,103.29 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Novo Nordisk INC | $694.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Aop Health US, LLC | $612.29 | 2025 | Rapiblyk |
| Abbott Laboratories | $595.55 | 2021-2025 | Jot Dx, Aveir |
| Amgen INC. | $567.36 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $533.37 | 2023-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $417.70 | 2023-2025 | Verquvo |
| Pfizer INC. | $303.56 | 2023-2025 | |
| Esperion Therapeutics, INC. | $294.39 | 2023-2025 | Nexletol |
| Irhythm Technologies, INC. | $274.45 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $253.06 | 2024-2025 | |
| Medtronic Vascular, INC. | $251.96 | 2019-2020 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Chhabra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.